Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Endocrinol Metab Clin North Am. 2011 Sep;40(3):509-18, viii. doi: 10.1016/j.ecl.2011.05.006. Epub 2011 Jul 12.
Many women take hormone therapy (HT) for menopausal symptom relief. Studies have tried to clarify whether various factors can modify the risk of HT, such as the age at initiation, dose, duration, or type of HT, or characteristics of the individual, such as family history or body mass index. The relative risks of breast cancer associated with HT across various subgroups of women should be considered similar, but absolute risks can vary significantly among women and this may inform individual decision making. For breast cancer survivors, systemic HT should be discouraged.
许多女性采用激素疗法（HT）缓解更年期症状。研究试图阐明各种因素是否可以改变 HT 的风险，例如起始年龄、剂量、持续时间或 HT 类型，或个体特征，如家族史或体重指数。应认为与 HT 相关的乳腺癌的相对风险在女性的各种亚组中相似，但绝对风险在女性中差异很大，这可能会影响个人决策。对于乳腺癌幸存者，应不鼓励使用全身 HT。
